Clinical trials: Afib
Atrial Fibrillation, Atrial Flutter
Strategy of Early Detection and Active Management of Supraventricular Arrhythmia With Telecardiology (SETAM)
This study investigates if the early detection and treatment of supraventricular arrhythmia (SVA) may help to prevent the progression of the arrhythmia and improve the clinical outcome.
- Conditions
- Atrial Fibrillation, Atrial Flutter, Atrial Tachycardia
- Trial name
- SETAM (NCT01108692)
- Testing
- Telecardiology
- Where
- 57 sites in France
- Volunteers
- 602 people
- Sponsor
- Biotronik France
Persistent Atrial Fibrillation
Endocardial Mapping With the CoreMap EP Mapping System
This is a global, multi-site, prospective, feasibility study.
- Trial name
- INvENI (NCT06529978)
- Testing
- CoreMap EP Mapping System Mapping, CoreMap EP Mapping System Map-Guided Ablation
- Where
- 4 sites in United States, Czechia
- Volunteers
- 245 people
- Sponsor
- CoreMap Inc.
Non-valvular Atrial Fibrillation (NVAF)
Early Post-marketing Study of Eliquis (Apixaban)
The primary objective of the study is to identify and describe any suspected (AEs) in all patients with NVAF treated with Apixaban, as a request of the National Center of Pharmacovigilance (CNFV) in Mexico.
- Trial name
- NCT02153424
- Testing
- Apixaban
- Where
- 2 sites in Mexico
- Sponsor
- Bristol-Myers Squibb
Atrial Fibrillation
High Intensity Focused Ultrasound (HIFU) Ablation System Study
The purpose of this study is to determine if the HIFU Pulmonary Vein Ablation System is effective in the treatment of paroxysmal Atrial Fibrillation compared to the control of best medical therapy with FDA approved antiarrhythmic…
- Trial name
- NCT00392106
- Testing
- propafenone, flecainide, dofetilide
- Where
- 21 sites in United States, Czechia
- Volunteers
- 240 people
- Sponsor
- ProRhythm, Inc.
Atrial Fibrillation, Renal Dysfunction
A Real World Evidence Retrospective Data Collection Study of Edoxaban and Rivaroxaban
This study aims to evaluate the recommended once-daily dosing of edoxaban and rivaroxaban in patients with atrial fibrillation (AF) and renal dysfunction in South Korea and Taiwan.
- Trial name
- NCT07874555
- Testing
- Edoxaban, Rivaroxaban
- Where
- 2 sites in South Korea, Taiwan
- Volunteers
- 8,265 people
- Sponsor
- Daiichi Sankyo
Non-valvular Atrial Fibrillation
A Nationwide Observational Study Looking at Effectiveness and Bleeding Complications of NOACs vs. VKA in Non-valvular Atrial Fibrillation Patients.
Using mandatory nationwide registries and possibly hospital electronic medical records in Norway, the researchers want to understand how well a group of drugs called "non-vitamin K antagonist oral anticoagulants" (rivaroxaban …
- Trial name
- PROTECT-AF (NCT03715725)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Apixaban (Eliquis), Dabigatran etexilate (Pradaxa)
- Where
- Norway
- Volunteers
- 70,000 people
- Sponsor
- Bayer
Paroxysmal Atrial Fibrillation (PAF)
Grid eXplore Mapping Study
The purpose of the trial is to find out if the Grid X Mapping Catheter and EnSite X EP System with EnSite X Software v3.1.1, the devices that are being studied, are safe and effective in treating Chinese patients who have atrial…
- Trial name
- NCT07421076
- Testing
- Grid X and EnSite X v3.1.1 Software
- Where
- 5 sites in China
- Volunteers
- 200 people
- Sponsor
- Abbott Medical Devices
Atrial Fibrillation
Late Phase 2 Study of DU-176b in Patients With Non-Valvular Atrial Fibrillation
The primary objective of this study is to compare the incidence of hemorrhagic events in patients treated for non-valvular atrial fibrillation with DU-176b at each dose level versus warfarin potassium (warfarin).
- Trial name
- NCT00829933
- Testing
- DU-176b tablets, Warfarin potassium tablets
- Where
- Japan
- Volunteers
- 536 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Venous Thrombosis, Pulmonary Embolism
Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (UK)
This prospective cohort study will provide information about: characteristics of Rivaroxaban use in patients who are prescribed Rivaroxaban for the first time compared to patients who are prescribed Warfarin for the first time…
- Conditions
- Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation, Acute Coronary Syndrome
- Trial name
- NCT01947998
- Testing
- Rivaroxaban (Xarelto, Bay59-7939), Warfarin, Antiplatelet drugs
- Where
- United Kingdom
- Volunteers
- 50,299 people
- Sponsor
- Bayer
Ischemic Stroke, Ischemia
Biomarkers of Acute Stroke in Clinic
The proposed study will investigate the clinical use of the ISCDX test that may differentiate between diverse stroke etiologies as listed below: Aim 1: Differentiate between cardioembolic and large artery atherosclerotic ischemic…
- Conditions
- Ischemic Stroke, Ischemia, Atrial Fibrillation, Transient Ischemic Attack
- Trial name
- BASIC (NCT03897478)
- Testing
- ISCDX blood test
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Ischemia Care LLC
Atrial Fibrillation
Phase 2 Study of Oral K201 for Prevention of AF Recurrence
To evaluate the safety, efficacy, and tolerability of 3 doses of K201 (oral) administered for up to 28 days in subjects with recent DC cardioversion to sinus rhythm from sustained symptomatic atrial fibrillation (AF duration >3…
- Trial name
- ARCTIC-AF (NCT01067833)
- Testing
- K201 Tablet
- Volunteers
- 300 people
- Sponsor
- Sequel Pharmaceuticals, Inc
Atrial Fibrillation, Atrial Flutter
Intravenous Tedisamil in the Rapid Conversion of Atrial Fibrillation or Flutter to Normal Sinus Rhythm in Female Subjects
The purpose of this study is to demonstrate the ability of tedisamil to convert atrial fibrillation or flutter into normal sinus rhythm (NSR) in female patients.
- Trial name
- NCT00126074
- Testing
- Tedisamil sesquifumarate
- Where
- 26 sites in United States, Bulgaria and 4 more
- Sponsor
- Solvay Pharmaceuticals
Atrial Fibrillation
A Study to Predict Atrial Fibrillation (AF) Burden in Participants With PAF and PsAF Treated With the VARIPULSE™ PFA Catheter
The purpose of this study is to evaluate how safe VARIPULSE™ Catheter is and how well it works in the treatment of participants with symptomatic paroxysmal atrial fibrillation (PAF; irregular heartbeat where episodes start and…
- Trial name
- SPECTRA-AF (NCT07788989)
- Testing
- VARIPULSE Catheter System (PVI), VARIPULSE Catheter System (PVI and PWI)
- Where
- United States
- Volunteers
- 2,300 people
- Sponsor
- Biosense Webster, Inc.
Atrial Fibrillation, Tachycardia, Supraventricular
Reducing Episodes by Septal Pacing Efficacy Confirmation Trial (RESPECT)
The purpose of this study is to find out if specialized programs in the AT500 and EnRhythm pacemakers will reduce the number of irregular heartbeat in the upper chamber of the heart and reduce symptoms (such as shortness of…
- Conditions
- Atrial Fibrillation, Tachycardia, Supraventricular, Arrhythmia, Bradycardia
- Trial name
- NCT00289289
- Testing
- Intervention Pacing Features
- Where
- 38 sites in United States, Canada
- Volunteers
- 400 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Atrial Fibrillation, Embolic Stroke of Undetermined Source
An Open-label Study of EZYPRO® in Atrial Fibrillation Detection on ESUS Patients
The aim of the study is to evaluate the effectiveness and safety of the 14-day continuous ECG patch monitor (EZYPRO®) compared with a 24-hour Holter monitor in the detection of atrial fibrillation (AF) among ESUS patients.
- Trial name
- NCT05089435
- Testing
- EZYPRO® ECG Recorder
- Where
- Taiwan
- Volunteers
- 500 people
- Sponsor
- Sigknow Biomedical Co., Ltd.
Atrial Fibrillation, Thromboembolism
AMPLATZER™ LAA Occluder Post Approval Study (PAS)
The aim of this multicenter, non-randomized observational post-approval is to compile real world outcome data on the use of an AMPLATZER LAA Occluder in subjects with non-valvular atrial fibrillation (NVAF).
- Conditions
- Atrial Fibrillation, Thromboembolism, Stroke
- Trial name
- NCT02964208
- Testing
- AMPLATZER™ LAA Occluder
- Where
- 22 sites in Argentina, Belgium and 5 more
- Volunteers
- 520 people
- Sponsor
- Abbott Medical Devices
Atrial Fibrillation
Edoxaban Treatment Versus Vitamin K Antagonist (VKA) in Patients With Atrial Fibrillation (AF) Undergoing Catheter Ablation
There are insufficient data on the safety and efficacy of edoxaban therapy in subjects with AF following catheter ablation. This phase 3b study is designed to evaluate the safety and to explore the efficacy of an edoxaban-based…
- Trial name
- ELIMINATE-AF (NCT02942576)
- Testing
- Edoxaban, VKA-Based Regimen
- Where
- 75 sites in Belgium, Canada and 9 more
- Volunteers
- 632 people
- Sponsor
- Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Atrial Fibrillation
Intra-Cardiac Echocardiography Guided Cardioversion(ICE-CHIP) Study
This is a sequential phase 1 and phase 2 study to evaluate the efficacy of intracardiac echocardiography to detect septal and left atrial pathology as compared to transesophageal echocardiography (Phase 1) and its value in a…
- Trial name
- ICE-CHIP (NCT00281073)
- Testing
- Intra-Cardiac Echocardiography guided Cardioversion, Intracardiac Echo, ICE
- Where
- 6 sites in United States, Netherlands
- Volunteers
- 95 people
- Sponsor
- EP MedSystems
Atrial Fibrillation
Verily Watch Cardio (AF and ECG) Study
This study is designed to evaluate the performance of the Verily Watch Cardio for recording electrocardiogram (ECG) and photoplethysmography (PPG) signals and detecting suspected atrial fibrillation (AF) episodes, in a…
- Trial name
- NCT06041373
- Testing
- Verily Watch Cardio, iRhythm Zio monitor, Schiller CARDIOVIT FT-1
- Where
- 3 sites in United States
- Sponsor
- Verily Life Sciences LLC
Paroxysmal Atrial Fibrillation (PAF)
Clinical Evaluation of the Blazer Open-Irrigated Ablation Catheter for the Treatment of Paroxysmal Atrial Fibrillation
The purpose of this study is to establish the safety and effectiveness of the Blazer Open-Irrigated radiofrequency ablation catheter for the treatment of drug refractory, recurrent, symptomatic, paroxysmal atrial fibrillation.
- Trial name
- ZERO-AF (NCT01687166)
- Testing
- Blazer Open-Irrigated Ablation Catheter (Boston Scientific), FDA Approved Open-Irrigated Ablation Catheter
- Where
- 38 sites in United States, Australia and 7 more
- Volunteers
- 398 people
- Sponsor
- Boston Scientific Corporation